Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 12,462 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cell Therapy Clear all
Terminated Phase 2 Interventional

Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma

NCT01617213
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan, Lenalidomide
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 21, 2026, 2:38 PM EDT
Recruiting Phase 2 Interventional

Autologous Stem Cell Transplant for Crohn's Disease

NCT03219359
View directory record Official record
Conditions
Crohn Disease
Interventions
Autologous stem cell transplant, Cyclophosphamide, Thymoglobulin, Methylprednisolone, Vedolizumab
Procedure · Drug
Lead sponsor
Aaron Etra
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

NCT06866262
View directory record Official record
Conditions
Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Inulin, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration
Procedure · Dietary Supplement · Biological + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Recruiting Phase 2 Interventional

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

NCT06815003
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Melphalan, Multigated Acquisition Scan, Questionnaire Administration, Tacrolimus, Vedolizumab
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Not applicable Interventional

Intravascular Volume Expansion to Neuroendocrine-Renal Function Profiles in Chronic Heart Failure

NCT04156854
View directory record Official record
Conditions
Heart Failure
Interventions
Quantitated Blood Volume Analysis
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis

NCT00040482
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cyclophosphamide, ATG, MESNA, Radiation therapy
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer

NCT00002679
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2002
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 26, 2009 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients

NCT01897688
View directory record Official record
Conditions
Type 1 Diabetes, Severe Hypoglycemic Unawareness
Interventions
Islet Cell Transplant
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

NCT02642042
View directory record Official record
Conditions
KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Docetaxel, Laboratory Biomarker Analysis, Trametinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
596
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Jonesboro, Arkansas + 375 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Enrolling by invitation Phase 4 Interventional

Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis

NCT06461442
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Cryotherapy, 5Fluorouracil
Procedure · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Early Phase 1 Interventional

Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer

NCT00278369
View directory record Official record
Conditions
Kidney Cancer
Interventions
aldesleukin, denileukin diftitox
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 21, 2026, 2:38 PM EDT
Recruiting Phase 3 Interventional

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

NCT07388524
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection, Computed Tomography, Patient Observation
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
106
States / cities
Beverly Hills, California • Los Angeles, California • Tarzana, California + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

NCT00107380
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, tositumomab and iodine I 131 tositumomab
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
78
States / cities
Anchorage, Alaska • Tucson, Arizona • Duarte, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 1 Interventional

Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia

NCT00626483
View directory record Official record
Conditions
Malignant Neoplasms Brain
Interventions
RNA-loaded dendritic cell vaccine, basiliximab
Biological · Drug
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 21, 2026, 2:38 PM EDT
Active, not recruiting Phase 1 Interventional

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

NCT03434769
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Cyclophosphamide, Fludarabine, CAR-T Cells
Drug · Biological
Lead sponsor
Benjamin Tomlinson
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
2
States / cities
St Louis, Missouri • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Terminated Phase 2 Interventional Results available

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT04047797
View directory record Official record
Conditions
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Ixazomib, Ixazomib Citrate, Rituximab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 21, 2026, 2:38 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

NCT03803774
View directory record Official record
Conditions
Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Sinonasal Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Birinapant, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00030420
View directory record Official record
Conditions
Lung Cancer
Interventions
Celecoxib, Docetaxel
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

NCT00059813
View directory record Official record
Conditions
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
recombinant interferon alfa, oblimersen sodium, pharmacological study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer

NCT00004013
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, paclitaxel
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 21, 2026, 2:38 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

NCT04581824
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Dostarlimab, Pembrolizumab, Chemotherapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Denver, North Carolina • Cincinnati, Ohio • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 1 Interventional Results available

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

NCT02133742
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Axitinib, MK-3475
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
19
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 3 Interventional

Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery

NCT00002670
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
chemotherapy, cisplatin, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2013
U.S. locations
22
States / cities
Tampa, Florida • Atlanta, Georgia • Decatur, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 21, 2026, 2:38 PM EDT
Terminated Phase 4 Interventional

Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A

NCT00621673
View directory record Official record
Conditions
Hemophilia A
Interventions
Kogenate (BAY 14-2222)
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 60 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Detroit, Michigan • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 21, 2026, 2:38 PM EDT